These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 18381774)

  • 1. Lessons from TGN1412 and TARGET: implications for observational studies and meta-analysis.
    Senn S
    Pharm Stat; 2008; 7(4):294-301. PubMed ID: 18381774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of biologics, lessons learnt from TGN1412.
    Stebbings R; Poole S; Thorpe R
    Curr Opin Biotechnol; 2009 Dec; 20(6):673-7. PubMed ID: 19892543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. On setting the first dose in man: quantitating biotherapeutic drug-target binding through pharmacokinetic and pharmacodynamic models.
    Lowe PJ; Tannenbaum S; Wu K; Lloyd P; Sims J
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):195-209. PubMed ID: 20050847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the utility of the Dirichlet distribution for meta-analysis of clinical studies.
    Sankoh AJ; Al-Osh M; Huque MF
    J Biopharm Stat; 1999 May; 9(2):289-306. PubMed ID: 10379695
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-Man (FIM) clinical trials post-TeGenero: a review of the impact of the TeGenero trial on the design, conduct, and ethics of FIM trials.
    Nada A; Somberg J
    Am J Ther; 2007; 14(6):594-604. PubMed ID: 18090886
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of one-step and two-step meta-analysis models using individual patient data.
    Mathew T; Nordström K
    Biom J; 2010 Apr; 52(2):271-87. PubMed ID: 20349448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis combining parallel and cross-over clinical trials. III: The issue of carry-over.
    Curtin F; Elbourne D; Altman DG
    Stat Med; 2002 Aug; 21(15):2161-73. PubMed ID: 12210631
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Glucosamine for osteoarthritis: part I, review of the clinical evidence.
    Biggee BA; McAlindon T
    Med Health R I; 2004 Jun; 87(6):176-9. PubMed ID: 15344672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learned from large-scale clinical trials.
    Deykin D
    Trans Am Clin Climatol Assoc; 1991; 102():96-104; discussion 104-5. PubMed ID: 2151835
    [No Abstract]   [Full Text] [Related]  

  • 10. Establishing risk of human experimentation with drugs: lessons from TGN1412.
    Kenter MJ; Cohen AF
    Lancet; 2006 Oct; 368(9544):1387-91. PubMed ID: 17046471
    [No Abstract]   [Full Text] [Related]  

  • 11. Further lessons from the TGN1412 tragedy.
    Goodyear MD
    BMJ; 2006 Aug; 333(7562):270-1. PubMed ID: 16888292
    [No Abstract]   [Full Text] [Related]  

  • 12. Performance-based readability testing of participant materials for a phase I trial: TGN1412.
    Knapp P; Raynor DK; Silcock J; Parkinson B
    J Med Ethics; 2009 Sep; 35(9):573-8. PubMed ID: 19717698
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Osteoarthritis antirheumatic drug trials. III. Setting the delta for clinical trials--results of a consensus development (Delphi) exercise.
    Bellamy N; Carette S; Ford PM; Kean WF; le Riche NG; Lussier A; Wells GA; Campbell J
    J Rheumatol; 1992 Mar; 19(3):451-7. PubMed ID: 1578462
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Practical approaches to dose selection for first-in-human clinical trials with novel biopharmaceuticals.
    Tibbitts J; Cavagnaro JA; Haller CA; Marafino B; Andrews PA; Sullivan JT
    Regul Toxicol Pharmacol; 2010 Nov; 58(2):243-51. PubMed ID: 20558225
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on TGN1412.
    Bhogal N; Combes R
    Altern Lab Anim; 2006 Jun; 34(3):351-6. PubMed ID: 16831066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
    Barriere SL; Guglielmo BJ
    Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A non-parametric procedure for evaluating treatment effect in the meta-analysis of survival data.
    Moodie PF; Nelson NA; Koch GG
    Stat Med; 2004 Apr; 23(7):1075-93. PubMed ID: 15057879
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of stopping rules on heterogeneity of results in overviews of clinical trials.
    Hughes MD; Freedman LS; Pocock SJ
    Biometrics; 1992 Mar; 48(1):41-53. PubMed ID: 1581492
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical and updated guidelines on performing meta-analyses of non-randomized studies in interventional cardiology.
    Navarese EP; Koziński M; Pafundi T; Andreotti F; Buffon A; Servi SD; Kubica J
    Cardiol J; 2011; 18(1):3-7. PubMed ID: 21305479
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis.
    Sokka T; Pincus T
    Arthritis Rheum; 2003 Feb; 48(2):313-8. PubMed ID: 12571838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.